A Phase 3 interventional study of sitagliptin phosphate and Comparator: metformin in Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 117th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 66th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 30 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 114th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 86 in phase 3, and was the 76th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sitagliptin + metformin
Drug: sitagliptin phosphate · Drug: Comparator: metformin
metformin + any other oral antidiabetic drug
Drug: Comparator: metformin · Drug: Comparator: Antidiabetic Standard of Care
metformin
Drug: Comparator: metformin
sitagliptin 100 mg Once a day (QD) for 24 weeks
Also known as: sitagliptin
metformin 850 mg Twice a day (BID) for 24 weeks
Also known as: metformin
metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
Also known as: metformin
Patient can take any oral antidiabetic drug (other than metformin)
Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24
Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.
Time frame: Baseline and 24 weeks
Patients were recruited in Principal Investigator's private practice, in Mexico City. First Patient Entered: 15 Feb 2007. Last Patient's Last Visit: 27 Jun 2008
| Milestone | Sitagliptin + Metformin | Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | Metformin Alone |
|---|---|---|---|
| Started | 36 | 23 | 9 |
| Completed | 36 | 23 | 9 |
| Not completed | 0 | 0 | 0 |
Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin + Metformin | — | 0/36 (0%) | 0/36 (0%) |
| Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | — | 0/23 (0%) | 1/23 (4.3%) |
| Metformin Alone | — | 0/9 (0%) | 0/9 (0%) |
| Event | Sitagliptin + Metformin | Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | Metformin Alone |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/36 | 1/23 | 0/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/36 | 1/23 | 0/9 |
| Age, Continuous(years) | Sitagliptin + Metformin | Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | Metformin Alone | Total |
|---|---|---|---|---|
| Mean | 54.2 ± 9.8 | 56.0 ± 8.5 | 53.3 ± 11.7 | 54.69 ± 9.55 |
| Sex: Female, Male(Participants) | Sitagliptin + Metformin | Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | Metformin Alone | Total |
|---|---|---|---|---|
| Female | 25 | 19 | 6 | 50 |
| Male | 11 | 4 | 3 | 18 |
| Body Mass Index (BMI)(kg/m2) | Sitagliptin + Metformin | Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | Metformin Alone | Total |
|---|---|---|---|---|
| Mean | 29.0 ± 4.5 | 28.8 ± 5.1 | 28.3 ± 5.2 | 28.84 ± 4.74 |
| Glycosylated Hemoglobin A1C (A1C)(Percent) | Sitagliptin + Metformin | Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | Metformin Alone | Total |
|---|---|---|---|---|
| Mean | 8.8 ± 1.5 | 8.0 ± 1.8 | 8.2 ± 1.1 | 8.47 ± 1.61 |
| Time since diagnosis of diabetes(Years) | Sitagliptin + Metformin | Metformin + Any Non-DPP-4i Oral Antidiabetic Drug | Metformin Alone | Total |
|---|---|---|---|---|
| Mean | 8.9 ± 7.1 | 6.8 ± 8.5 | 10.9 ± 7.7 | 8.43 ± 7.68 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
Ran from Feb 2007 to primary completion in Jun 2008, 16 months.
Results were first posted in Apr 2011, 2 years 9 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin